IDENTIFICATION OF MODIFIED AND NATURAL HEL PEPTIDE FRAGMENTS PRESENTED BY MHC
MHC 呈现的修饰和天然 HEL 肽片段的鉴定
基本信息
- 批准号:8361330
- 负责人:
- 金额:$ 2.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-01-01 至 2011-12-31
- 项目状态:已结题
- 来源:
- 关键词:AftercareAntigen-Presenting CellsAntigensChromatographyComplexFundingGrantHen Egg LysozymeHigh Pressure Liquid ChromatographyHistocompatibility Antigens Class IIImmunologyMajor Histocompatibility ComplexMass Spectrum AnalysisMethodsModelingMutateNational Center for Research ResourcesPeptide FragmentsPeptidesPrincipal InvestigatorProteinsResearchResearch InfrastructureResourcesSeriesSourceSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationSurface AntigensT cell responseT-LymphocyteUnited States National Institutes of HealthWorkantigen processingbiomedical resourcecostnano-electrosprayresponse
项目摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
The immuno response of T cells requires an antigen to be recognized. We have demonstrated before with the model protein antigen Hen Egg Lysozyme (HEL), that this response to proteins involves unfolding and degradation to peptides that are recognized on the surface of antigen-presenting cells (APC) in association with the major histocompatibility complex (MHC) molecules. Previous results showed that T-cells, after activation by I-Ak type APC, respond to a synthetic 10-mer residue, HEL 51-62. Similarly, T cells after activation by I-Ek type APC, respond to a 13-mer, HEL 84-96. HPLC chromatography of the mixture extracted from MHC class II complexes of APC after treatment with HEL gave the immuno active fractions that were analyzed by MALDI-TOF and cf-FAB MS. The major components were HEL 48-63, 48-62, 48-61 for I-Ak type APC and HEL 84-97, 84-98, 84-102 for I-Ek type APC. To extend the understanding of the protein antigen processing mechanism producing the peptides that are presented to the T cells, we are working on characterizing peptides produced from a series of mutated HEL proteins. We are developing methods involving MALDI, and electrospray and nano-electrospray tandem MS to solve these important immunology problems.
该子项目是利用资源的众多研究子项目之一
由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持
并且子项目的主要研究者可能是由其他来源提供的,
包括其他 NIH 来源。 子项目可能列出的总成本
代表子项目使用的中心基础设施的估计数量,
NCRR 赠款不直接向子项目或子项目工作人员提供资金。
T 细胞的免疫反应需要抗原才能被识别。 我们之前已经用模型蛋白抗原鸡蛋溶菌酶 (HEL) 证明,这种对蛋白质的反应涉及到肽的解折叠和降解,这些肽在抗原呈递细胞 (APC) 表面上与主要组织相容性复合体 (MHC) 分子相关识别。 先前的结果表明,T 细胞在被 I-Ak 型 APC 激活后,会对合成的 10 聚体残基 HEL 51-62 做出反应。 同样,T 细胞在被 I-Ek 型 APC 激活后,会对 13 聚体 HEL 84-96 做出反应。 用 HEL 处理后,对从 APC 的 MHC II 类复合物中提取的混合物进行 HPLC 色谱分析,得到免疫活性级分,并通过 MALDI-TOF 和 cf-FAB MS 进行分析。 I-Ak 型 APC 的主要部件为 HEL 48-63、48-62、48-61,I-Ek 型 APC 的主要部件为 HEL 84-97、84-98、84-102。为了加深对产生呈递给 T 细胞的肽的蛋白质抗原加工机制的理解,我们正在研究由一系列突变的 HEL 蛋白产生的肽的特征。 我们正在开发涉及 MALDI、电喷雾和纳米电喷雾串联 MS 的方法来解决这些重要的免疫学问题。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
EMIL Raphael UNANUE其他文献
EMIL Raphael UNANUE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('EMIL Raphael UNANUE', 18)}}的其他基金
Identification of relevant peptides involved in the initiation and progression of autoimmune diabetes
鉴定参与自身免疫性糖尿病发生和进展的相关肽
- 批准号:
10246429 - 财政年份:2018
- 资助金额:
$ 2.68万 - 项目类别:
Identification of relevant peptides involved in the initiation and progression of autoimmune diabetes
鉴定参与自身免疫性糖尿病发生和进展的相关肽
- 批准号:
9689765 - 财政年份:2018
- 资助金额:
$ 2.68万 - 项目类别:
AUTOIMMUNE DIABETES: EARLY EVENTS IN ISLETS OF LANGERHANS
自身免疫性糖尿病:朗格汉斯岛的早期事件
- 批准号:
9197630 - 财政年份:2015
- 资助金额:
$ 2.68万 - 项目类别:
CHARACTERIZATION OF ANTIGENIC PEPTIDES PRESENTED BY I-AG7
I-AG7 呈现的抗原肽的表征
- 批准号:
8361393 - 财政年份:2011
- 资助金额:
$ 2.68万 - 项目类别:
IDENTIFICATION OF MODIFIED AND NATURAL HEL PEPTIDE FRAGMENTS PRESENTED BY MHC
MHC 呈现的修饰和天然 HEL 肽片段的鉴定
- 批准号:
8168678 - 财政年份:2010
- 资助金额:
$ 2.68万 - 项目类别:
PEPTIDES IDENTIFIED FROM THE TYPE I DIABETES ASSOCIATED MHC CLASS I-H2-KD
从 I 型糖尿病相关 MHC I-H2-KD 类中鉴定出的肽
- 批准号:
8168690 - 财政年份:2010
- 资助金额:
$ 2.68万 - 项目类别:
CHARACTERIZATION OF ANTIGENIC PEPTIDES PRESENTED BY I-AG7
I-AG7 呈现的抗原肽的表征
- 批准号:
8168793 - 财政年份:2010
- 资助金额:
$ 2.68万 - 项目类别:
相似海外基金
Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
- 批准号:
10751133 - 财政年份:2023
- 资助金额:
$ 2.68万 - 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
- 批准号:
10696138 - 财政年份:2022
- 资助金额:
$ 2.68万 - 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
- 批准号:
10663066 - 财政年份:2022
- 资助金额:
$ 2.68万 - 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
- 批准号:
10537159 - 财政年份:2022
- 资助金额:
$ 2.68万 - 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
- 批准号:
21K08723 - 财政年份:2021
- 资助金额:
$ 2.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
- 批准号:
10156950 - 财政年份:2021
- 资助金额:
$ 2.68万 - 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
- 批准号:
10631854 - 财政年份:2021
- 资助金额:
$ 2.68万 - 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
- 批准号:
10153927 - 财政年份:2021
- 资助金额:
$ 2.68万 - 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
- 批准号:
10331830 - 财政年份:2021
- 资助金额:
$ 2.68万 - 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
- 批准号:
20K16294 - 财政年份:2020
- 资助金额:
$ 2.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




